Part-Time
People Operations Specialist
Alector
51-200 employees
Biopharmaceutical R&D for neurodegenerative therapies
Compensation Overview
$40 - $50/hr
San Bruno, CA, USA
Hybrid
Onsite three days per week at South San Francisco headquarters.
 People & HR (1) |
|---|
- You are a proactive self-starter who asks thoughtful questions and seeks effective solutions.
- You are an active user of large language models (LLMs) with a strong interest in advancing AI-driven workflows; you have hands-on experience applying automation tools to real business processes.
- You have experience serving as a front-line resource for employees and resolving issues end-to-end.
- You bring an analytical mindset, with experience in data-driven or operational roles and an interest in People/HR functions.
- You have demonstrated success managing cross-functional projects independently with strong attention to detail.
- Deliver exceptional employee support! Serve as a front-line resource for benefits and People Operations inquiries, resolving issues end-to-end with speed, clarity, and care.
- Reimagine how we work! Evaluate, redesign, and automate workflows using AI, LLMs, and integration tools to significantly reduce manual effort and increase accuracy.
- Elevate operational excellence! Ensure data integrity, compliance, and seamless execution across the employee lifecycle while proactively identifying and correcting discrepancies.
- Strengthen cross-functional systems! Partner with IT, Payroll, Finance, Facilities, and Talent Acquisition to optimize integrations and improve data flows.
- Drive high-impact improvements! Identify and implement system enhancements, workflow automations, and key initiatives (e.g., open enrollment), from concept through continuous optimization—including integrating innovative AI solutions to accelerate outcomes and conserve resources!
- 4+ years of experience in People Operations or HR in a highly execution-focused environment.
- Experience optimizing HRIS platforms and building system integrations.
- Familiarity with California employment law and operating in a regulated, publicly traded environment.
- Comfort working in a fast-paced environment with evolving priorities and opportunities to innovate.
Alector is a biopharmaceutical company that develops therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. It uses insights from immunology, neurology, and human genetics to create medicines that help the body heal itself. The company focuses on researching and developing novel therapeutic candidates, mainly through early-stage clinical trials to quickly gather disease-specific data and improve the chances of success. Revenue and funding come from partnerships, grants, and eventual product commercialization. Alector aims to advance treatments for unmet medical needs in neurodegenerative diseases by pursuing a pipeline that combines scientific findings with strategic drug development.
Company Size
51-200
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2013
Simplify's Take
What believers are saying
- AL037/AL137-ABC anti-amyloid antibody targets validated epitope with reduced ARIA risk versus competitors.
- Cash position of $206.5 million funds operations through 2027 and preclinical pipeline advancement.
- Analyst consensus price target 48% above current stock price signals potential undervaluation opportunity.
What critics are saying
- AL002 Phase 2 failure and GSK latozinemab efficacy stumble eliminate two major clinical assets.
- Hercules Capital debt covenants trigger default from Q1 2026 revenue miss, forcing $10M repayment.
- 13% workforce layoff signals cash constraints and accelerates talent exodus to better-funded competitors.
What makes Alector unique
- Proprietary Alector Brain Carrier technology enables blood-brain barrier penetration for siRNA and protein therapeutics.
- Genetically-validated target selection from human genetics, neuroscience, and immunology insights reduces clinical failure risk.
- AL050 GCase enzyme replacement therapy addresses GBA mutations in Parkinson's and Lewy body dementia.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Alector who can refer or advise you
Benefits
Flexible Work Hours
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 3%2 year growth
↑ 6%Alector, a South San Francisco-based biotechnology company, reported a fourth-quarter loss of $37.3 million, or 34 cents per share, beating analyst expectations of a 39-cent loss. The company posted revenue of $6.2 million, exceeding forecasts of $3.1 million from three analysts surveyed by Zacks Investment Research. For the full year, Alector's loss widened to $142.9 million, or $1.39 per share, with revenue of $21 million. The company's shares closed at $2.39 on Wednesday, up from $1.77 a year earlier.
SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2024, at 8:40 am ET.A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event.About AlectorAlector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer’s disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline
Additionally, Alector will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York on May 20, 2025, at 12:00 p.m. ET.
In another strategy, Alector, in collaboration with GSK, is developing the monoclonal antibody latozinemab (AL001), which works by blocking progranulin degradation to boost its availability.
As part of cost-cutting efforts, Alector is letting go of about 25 people as it focuses on advancing its preclinical and research pipeline.